Table 4.
Burden and association between zoster and each primary outcome among all immunocompetent adults in Clinical Practice Research Datalink GOLD or Aurum, overall and by age at zoster diagnosis, in the 3 months following zoster
| Zoster, n (%) | No zoster, n (%) | Age‐ and sex‐adjusted HR (95% CI)a | Fully adjusted HR (95% CI)b | P‐valuec | |
|---|---|---|---|---|---|
| All neurologicald | 1160 (0·6) | 3127 (0·2) | 3·78 (3·51–4·08) | 3·63 (3·35–3·94) | – |
| All ocular | 4662 (2·6) | 23 079 (1·3) | 2·08 (2·01–2·15) | 1·99 (1·92–2·07) | |
| All cutaneouse | 1231 (0·7) | 7207 (0·4) | 1·66 (1·55–1·77) | 1·64 (1·52–1·77) | |
| All visceral | 4719 (2·6) | 33 430 (1·9) | 1·41 (1·37–1·46) | 1·30 (1·25–1·35) | |
| By age (years) | |||||
| All neurologicald | |||||
| < 50 | 253 (0·5) | 361 (0·07) | 7·13 (6·07–8·39) | 6·58 (5·51–7·85) | < 0·001 |
| ≥ 50 | 907 (0·7) | 2766 (0·2) | 3·22 (2·96–3·51) | 3·13 (2·86–3·44) | |
| All ocular | |||||
| < 50 | 650 (1·3) | 2364 (0·5) | 2·81 (2·58–3·07) | 2·57 (2·34–2·83) | < 0·001 |
| ≥ 50 | 4012 (3·1) | 20 715 (1·6) | 1·97 (1·90–2·05) | 1·91 (1·84–1·99) | |
| All cutaneouse | |||||
| < 50 | 163 (0·3) | 651 (0·1) | 2·54 (2·14–3·02) | 2·44 (2·03–2·95) | < 0·001 |
| ≥ 50 | 1068 (0·8) | 6556 (0·5) | 1·55 (1·43–1·67) | 1·55 (1·43–1·68) | |
| All visceral | |||||
| < 50 | 635 (1·3) | 3913 (0·8) | 1·66 (1·53–1·81) | 1·53 (1·39–1·67) | < 0·001 |
| ≥ 50 | 4084 (3·1) | 29 517 (2·3) | 1·37 (1·32–1·43) | 1·27 (1·22–1·32) | |
HR, hazard ratio; CI, confidence interval. aCox model with age as the underlying timescale. bAdditionally adjusted for rheumatoid arthritis, inflammatory bowel disease, systemic lupus erythematosus, socioeconomic status, smoking status, body mass index, depression, asthma, chronic obstructive pulmonary disorder, chronic kidney disease, liver disease and diabetes. c P‐value for interaction. dNot including Ramsay Hunt syndrome or postherpetic neuralgia. eNot including disseminated zoster.